Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Rönnblom Lars) "

Sökning: WFRF:(Rönnblom Lars)

Sortera/gruppera träfflistan
  • Klareskog, Lars, et al. (författare)
  • Vad är reumatologi?
  • 2017. - 3
  • Ingår i: Reumatologi. - 9789144115108 ; , s. 21-24
  • Bokkapitel (populärvet., debatt m.m.)
  • Sigurdsson, Snaevar, et al. (författare)
  • Association of a Haplotype in the Promoter Region of the Interferon Regulatory Factor 5 Gene With Rheumatoid Arthritis
  • 2007
  • Ingår i: Arthritis and Rheumatism. - : Wiley. - 0004-3591 .- 1529-0131. ; 56:7, s. 2202-2210
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective. To determine whether genetic variants of the interferon regulatory factor 5 (IRF-5) and Tyk-2 genes are associated with rheumatoid arthritis (RA). Methods. Five single-nucleotide polymorphisms (SNPs) in IRF5 and 3 SNPs in Tyk2 were analyzed in a Swedish cohort of 1,530 patients with RA and 881 controls. A replication study was performed in a Dutch cohort of 387 patients with RA and 181 controls. All patient sera were tested for the presence of autoantibodies against cyclic citrullinated peptides (anti-CCP). Results. Four of the 5 SNPs located in the 5' region of IRF5 were associated with RA, while no association was observed with the Tyk2 SNPs. The minor alleles of 3 of the IRF5 SNPs, which were in linkage disequilibrium and formed a relatively common haplotype with a frequency of ∼0.33, appeared to confer protection against RA. Although these disease associations were seen in the entire patient group, they were mainly found in RA patients who were negative for anti-CCP. A suggestive association of IRF5 SNPs with anti-CCP-negative RA was also observed in the Dutch cohort. Conclusion. Given the fact that anti-CCP-negative RA differs from anti-CCP-positive RA with respect to genetic and environmental risk factor profiles, our results indicate that genetic variants of IRF5 contribute to a unique disease etiology and pathogenesis in anti-CCP-negative RA.
  • Chemin, Karine, et al. (författare)
  • A Novel HLA-DRB1*10:01-Restricted T Cell Epitope From Citrullinated Type II Collagen Relevant to Rheumatoid Arthritis
  • 2016
  • Ingår i: Arthritis & Rheumatology. - : Wiley. - 2326-5191 .- 2326-5205. ; 68:5, s. 1124-1135
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective. Antibodies against citrullinated type II collagen (Cit-CII) are common in the sera and synovial fluid of patients with rheumatoid arthritis (RA); however, the known T cell epitope of CII is not dependent on citrullination. The aim of this study was to identify and functionally characterize the Cit-CII-restricted T cell epitopes that are relevant to RA. Methods. Peripheral blood mononuclear cells (PBMCs) from HLA-DRB1*10:01-positive patients with RA and healthy donors were stimulated in vitro with candidate CII peptides. CD154 up-regulation was measured as a marker of antigen-specific activation, and anti-HLA-DR-blocking experiments confirmed HLA restriction. Cytokine production was measured using a Luminex technique. Direct peptide-binding assays using HLA-DRB1*10:01 and HLA-DRB1*04:01 monomeric proteins were performed. The T cell receptor (TCR) beta-chain of CD154-enriched antigen-specific T cells was analyzed using high-throughput sequencing. Results. A novel Cit-CII peptide was identified based on its ability to activate CD4+ T cells from HLA-DRB1*10:01-positive individuals. When stimulated in vitro, Cit-CII autoreactive T cells produced proinflammatory cytokines. Cit-CII311-325 bound (with low affinity) to HLA-DRB1*10:01 but not to HLA-DRB1*04:01, while the native form was unable to bind either protein. In addition, highly expanded clones were identified in the TCR beta repertoire of Cit-CII311-325-stimulated PBMCs. Conclusion. These results illustrate the ability of the citrullination process to create T cell epitopes from CII, a cartilage-restricted protein that is relevant to RA pathogenesis. The exclusive binding of Cit-CII311-325 to HLA-DRB1*10:01 suggests that recognition of citrullinated epitopes might vary between individuals carrying different RA-associated HLA-DR molecules.
  • Eloranta, Maija-Leena, et al. (författare)
  • Type I interferon system activation and association with disease manifestations in systemic sclerosis
  • 2010
  • Ingår i: Annals of the Rheumatic Diseases. - : BMJ. - 0003-4967 .- 1468-2060. ; 69:7, s. 1396-1402
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVES: To study the presence of interferogenic autoantibodies in systemic sclerosis (SSc) and their correlation with clinical manifestations, serum levels of interferon alpha (IFNalpha) and chemokines of importance in the disease process. METHODS: Peripheral blood mononuclear cells (PBMCs) or purified plasmacytoid dendritic cells (pDCs) from healthy donors were stimulated with sera from patients with SSc (n=70) or healthy individuals (n=30), together with necrotic or apoptotic cell material. The IFNalpha produced and serum levels of IFNalpha, IFN-inducible protein-10 (IP-10)/chemokine (C-X-C motif) ligand 10, monocyte chemoattractant protein-1 (MCP-1)/(C-C motif) ligand-2 (CCL-2), macrophage inflammatory protein-1alpha (MIP-1alpha)/CCL-3 and RANTES/CCL-5 were measured and correlated with the presence of autoantibodies and clinical manifestations in the patients with SSc. RESULTS: Sera from both diffuse SSc and limited SSc contained interferogenic antibodies, which correlated with the presence of anti-ribonucleoprotein and anti-Sjögren syndrome antigen autoantibodies. The pDCs were responsible for the IFNalpha production which required interaction with FcgammaRII and endocytosis. Increased serum levels of IP-10 were associated with vascular manifestations such as cardiac involvement (p=0.027) and pulmonary arterial hypertension (p=0.036). Increased MCP-1 or IFNalpha serum levels were associated with lung fibrosis (p=0.019 and 0.048, respectively). Digital ulcers including digital loss were associated with increased serum levels of IFNalpha (p=0.029). CONCLUSION: An activated type I IFN system previously seen in several other systemic autoimmune diseases is also present in SSc and may contribute to the vascular pathology and affect the profibrotic process.
  • Folkersen, Lasse, et al. (författare)
  • Integration of known DNA, RNA and protein biomarkers provides prediction of anti-TNF response in rheumatoid arthritis : results from the COMBINE study.
  • 2016
  • Ingår i: Molecular Medicine. - : Springer Science and Business Media LLC. - 1076-1551 .- 1528-3658. ; 22, s. 322-328
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: In rheumatoid arthritis (RA) several recent efforts have sought to discover means of predicting which patients would benefit from treatment. However, results have been discrepant with few successful replications. Our objective was to build a biobank with DNA, RNA and protein measurements to test the claim that the current state-of-the-art precision medicine will benefit RA patients.METHODS: We collected 451 blood samples from 61 healthy individuals and 185 RA patients initiating treatment, before treatment initiation and at a 3 month follow-up time. All samples were subjected to high-throughput RNA sequencing, DNA genotyping, extensive proteomics and flow cytometry measurements, as well as comprehensive clinical phenotyping. Literature review identified 2 proteins, 52 single-nucleotide polymorphisms (SNPs) and 72 gene-expression biomarkers that had previously been proposed as predictors of TNF inhibitor response (∆DAS28-CRP).RESULTS: From these published TNFi biomarkers we found that 2 protein, 2 SNP and 8 mRNA biomarkers could be replicated in the 59 TNF initiating patients. Combining these replicated biomarkers into a single signature we found that we could explain 51% of the variation in ∆DAS28-CRP. This corresponds to a sensitivity of 0.73 and specificity of 0.78 for the prediction of three month ∆DAS28-CRP better than -1.2.CONCLUSIONS: The COMBINE biobank is currently the largest collection of multi-omics data from RA patients with high potential for discovery and replication. Taking advantage of this we surveyed the current state-of-the-art of drug-response stratification in RA, and identified a small set of previously published biomarkers available in peripheral blood which predicts clinical response to TNF blockade in this independent cohort.
  • Houtman, Miranda, et al. (författare)
  • Five commercially-available antibodies react differentially with allelic forms of human HLA-DR beta chain
  • 2022
  • Ingår i: Molecular Immunology. - : Elsevier BV. - 0161-5890 .- 1872-9142. ; 152, s. 106-110
  • Tidskriftsartikel (refereegranskat)abstract
    • Allelic variants of HLA-DRB1 have been associated with a variety of autoimmune and infectious diseases. Although the precise molecular mechanisms by which HLA-DRB1 alleles predispose to a particular disease are currently unclear, it has been shown that mRNA expression levels of HLA-DRB1 are dependent on the different alleles. We aimed to measure HLA-DR beta chain levels in peripheral blood mononuclear cells of individuals carrying HLA-DRB1*03:01/*04:01 and HLA-DRB1*03:01/*15:01 alleles by western blotting, using five commercially-available HLA-DRB antibodies. We observed highly heterogeneous binding of the tested antibodies to the different allelic forms of the HLA-DR beta chain. Overall, we show that current immunological research that employs available antibodies to detect HLA-DR beta chains is biased towards detection of specific variants of the protein; this may cause significant discrepancy in quantification of protein expression in a heterogeneous human population.
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (236)
forskningsöversikt (18)
annan publikation (12)
doktorsavhandling (12)
bokkapitel (6)
konferensbidrag (2)
visa fler...
visa färre...
Typ av innehåll
refereegranskat (204)
övrigt vetenskapligt/konstnärligt (76)
populärvet., debatt m.m. (6)
Rönnblom, Lars (274)
Eloranta, Maija-Leen ... (124)
Nordmark, Gunnel (74)
Sandling, Johanna K. (56)
Gunnarsson, Iva (50)
Svenungsson, Elisabe ... (46)
visa fler...
Jönsen, Andreas (41)
Rantapää-Dahlqvist, ... (36)
Syvänen, Ann-Christi ... (35)
Sjöwall, Christopher (35)
Leonard, Dag, 1975- (34)
Bengtsson, Anders A. (31)
Syvänen, Ann-Christi ... (27)
Wahren-Herlenius, Ma ... (25)
Alm, Gunnar (25)
Omdal, Roald (24)
Imgenberg-Kreuz, Jul ... (24)
Tandre, Karolina (22)
Padyukov, Leonid (22)
Bengtsson, Anders (21)
Eriksson, Per (20)
Berggren, Olof (20)
Lindblad-Toh, Kersti ... (19)
Sturfelt, Gunnar (18)
Jonsson, Roland (18)
Alexsson, Andrei (16)
Theander, Elke (16)
Alm, Gunnar V. (16)
Leonard, Dag (16)
Truedsson, Lennart (14)
Hagberg, Niklas (13)
Hagberg, Niklas, 197 ... (13)
Criswell, Lindsey A. (12)
Bianchi, Matteo (12)
Kämpe, Olle (11)
Klareskog, Lars (11)
Sigurdsson, Snaevar (11)
Jonsson, R (10)
Bengtsson, Christine (10)
Pucholt, Pascal, Dr, ... (10)
Mandl, Thomas (9)
Carlsson Almlöf, Jon ... (9)
Wang, Chuan (9)
Pastinen, Tomi (9)
Omdal, R (9)
Rönnelid, Johan (9)
Zickert, Agneta (9)
Hultin-Rosenberg, Li ... (9)
Behrens, Timothy W (9)
Graham, Robert R (9)
visa färre...
Uppsala universitet (258)
Karolinska Institutet (65)
Umeå universitet (34)
Lunds universitet (32)
Linköpings universitet (20)
Sveriges Lantbruksuniversitet (14)
visa fler...
Göteborgs universitet (9)
Örebro universitet (4)
Kungliga Tekniska Högskolan (3)
Högskolan i Gävle (1)
visa färre...
Engelska (272)
Odefinierat språk (9)
Svenska (5)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (192)
Naturvetenskap (6)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy